| 000 | 01753 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515151956.0 | ||
| 264 | 0 | _c20090519 | |
| 008 | 200905s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdn656 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoy, A | |
| 245 | 0 | 0 |
_aBortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMar 2009 |
||
| 300 |
_a520-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBoronic Acids _xadverse effects |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrazines _xadverse effects |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBernstein, S H | |
| 700 | 1 | _aKahl, B S | |
| 700 | 1 | _aDjulbegovic, B | |
| 700 | 1 | _aRobertson, M J | |
| 700 | 1 | _ade Vos, S | |
| 700 | 1 | _aEpner, E | |
| 700 | 1 | _aKrishnan, A | |
| 700 | 1 | _aLeonard, J P | |
| 700 | 1 | _aLonial, S | |
| 700 | 1 | _aNasta, S | |
| 700 | 1 | _aO'Connor, O A | |
| 700 | 1 | _aShi, H | |
| 700 | 1 | _aBoral, A L | |
| 700 | 1 | _aFisher, R I | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 20 _gno. 3 _gp. 520-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdn656 _zAvailable from publisher's website |
| 999 |
_c18527479 _d18527479 |
||